目的 探讨血必净注射液联合注射用哌拉西林钠他唑巴坦钠治疗脓毒症的效果。方法 选取2022年2月—2024年1月苏州第九人民医院收治的96例脓毒症患者资料，根据用药差别将患者分为对照组（50例）和治疗组（46例）。对照组静滴注射用哌拉西林钠他唑巴坦钠，4.5 g药物以20 mL灭菌注射用水充分溶解后与100 mL生理盐水混匀，1次/8 h。治疗组在对照组基础上静滴血必净注射液，将100 mL药品与100 mL生理盐水混匀，2次/d。两组患者治疗7 d后评估疗效。比较两组临床疗效、病情程度、血清炎性因子。结果 治疗组的总有效率为86.96%，对照组的总有效率为70.00%，组间比较差异显著（P＜0.05）。治疗后，两组急性生理与慢性健康评分（APACHE Ⅱ）、序贯器官衰竭评分（SOFA）评分均降低（P＜0.05），且治疗组的APACHE Ⅱ、SOFA评分均低于对照组（P＜0.05）。治疗后，两组血清降钙素原（PCT）、高迁移率蛋白1（HMGB1）、白细胞介素-6（IL-6）、C反应蛋白（CRP）水平均降低（P＜0.05），且治疗组血清PCT、HMGB1、IL-6、CRP水平低于对照组（P＜0.05）。结论 在注射用哌拉西林钠他唑巴坦钠治疗基础上加用血必净注射液可提高脓毒症的临床疗效，促进疾病转归，减轻炎症反应。

Objective To explore the efficacy of Xuebijing Injection combined with Piperacillin Sodium and Tazobactam Sodium for injection in treatment of sepsis. Methods Clinical data from 96 sepsis patients admitted to Suzhou Ninth People’s Hospital from February 2022 to January 2024 were selected, and the patients were divided into control group (50 cases) and treatment group (46 cases) based on medication differences. The control group received intravenous infusion of Piperacillin Sodium and Tazobactam Sodium for injection, 4.5 g drug fully dissolved in 20 mL sterile injection water and mixed with 100 mL physiological saline for once per 8 h. The treatment group received intravenous infusion of Xuebijing Injection on the basis of the control group, and 100 mL drug was mixed with 100 mL physiological saline, twice daily. The efficacy of two groups of patients was evaluated after 7 d of treatment. The clinical efficacy, severity of illness, and serum inflammatory factors were compared between two groups. Results The total effective rate of the treatment group was 86.96%, while the total effective rate of the control group was 70.00%, and the difference was significant between two groups (P < 0.05). After treatment, APACHE II and SOFA scores of two groups decreased (P < 0.05), and APACHE II and SOFA scores of the treatment group were lower than those of the control group (P < 0.05). After treatment, the serum levels of PCT, HMGB1, IL-6, and CRP in two groups decreased (P < 0.05), and the serum levels of PCT, HMGB1, IL-6, and CRP in the treatment group were lower than those in the control group (P < 0.05). Conclusion The combination of Xuebijing Injection and Piperacillin Sodium and Tazobactam Sodium for injection can improve clinical efficacy in treatment of sepsis, promote disease progression, and alleviate inflammatory reactions.

R977

苏州市第九人民医院科研启动基金立项项目（YK202121）